News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Biolex, Inc. Pulls Planned IPO Due to Market Conditions
February 4, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Feb 1 (Reuters) - Clinical-stage biopharmaceutical company Biolex Inc on Friday canceled a planned initial public offering, citing market conditions.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Gene editing
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
December 1, 2025
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
November 25, 2025
·
3 min read
·
Annalee Armstrong
Drug Development
CRO Boom in APAC Region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
November 19, 2025
·
9 min read
·
Tristan Manalac
